Product information
From Health Canada
No match found
No other product was found with the same active ingredient group.
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Cancelled Pre Market
Current status date:
2022-09-26
Original market date: See footnote 1
Product name:
QTERN
DIN:
02459175
Product Monograph/Veterinary Labelling:
Date:
2021-06-29
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
ASTRAZENECA CANADA INC
1004 Middlegate Road, Suite 5000
Mississauga
Ontario
Canada
L4Y 1M4
Class:
Human
Dosage form(s):
Tablet
Route(s) of administration:
Oral
Number of active ingredient(s):
2
Schedule(s):
Prescription
American Hospital Formulary Service (AHFS): See footnote 3
68:20.05
Anatomical Therapeutic Chemical (ATC): See footnote 4
A10BD21 SAXAGLIPTIN AND DAPAGLIFLOZIN
Active ingredient group (AIG) number:See footnote5
0258571001
| Active ingredient(s) See footnote8 | Strength |
|---|---|
| DAPAGLIFLOZIN (DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE) | 5 MG |
| SAXAGLIPTIN (SAXAGLIPTIN HYDROCHLORIDE) | 5 MG |
Risk Management Plans See footnote 7
A Risk Management Plan (RMP) for this product was submitted.